LOUISVILLE, Colo., Nov. 15 /PRNewswire-FirstCall/ -- Replidyne, Inc. announced today the appointment of two new senior staff members, J.C. Lee, Ph.D. as Vice President, Manufacturing and Ms. Sabrina B. Oei as Director of Investor & Public Relations.
Dr. Lee brings more than 20 years of experience in formulation development to Replidyne as the Vice President, Manufacturing. During those years, he successfully brought five products from prototype formulations to clinical trials, registration and commercial launch in the U.S. and Europe. Dr. Lee spent 12 years with Roche Bioscence/Syntex, leaving as the Acting Director of Formulation Development, and most recently served as Vice President, Development, with Cellegy Pharmaceuticals, leading the development efforts on four topical programs. At Replidyne, Dr. Lee will oversee all manufacturing activities at Replidyne focusing initially on developing the pediatric formulation for Replidyne’s lead product candidate, faropenem medoxomil, and its topical product candidate REP8839.
Ms. Oei joins Replidyne as the Director of Investor & Public Relations having managed global communications for Roche Pharmaceuticals’ licensing and business development department, Pharma Partnering, based in Basel, Switzerland. Prior to Roche, Ms. Oei was an analyst with Recombinant Capital, a consulting firm specializing in biotech alliances, in its European and San Francisco, CA offices. Most recently, Ms. Oei managed the healthcare public relations company Sabra Communications. Ms. Oei will be Replidyne’s primary contact for all public and investor inquiries.
“By attracting such qualified professionals to these key roles within Replidyne, we are continuing to build a deep and experienced team,” said Kenneth J. Collins, Replidyne’s President and Chief Executive Officer. “Our people are a key asset that will enable us to achieve our long-term potential.”
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne’s lead product, faropenem medoxomil, is a novel oral, community antibiotic that is expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. In February 2006, Replidyne entered into a partnership agreement with Forest Laboratories to develop and commercialize faropenem medoxomil in the US. An IND for Replidyne’s second drug candidate, REP8839, was submitted to the FDA in May 2006. REP8839 is a topical anti-infective product under development for the treatment of skin and wound infections, and the prevention of S. aureus infections, including multiple antibiotic-resistant S. aureus (MRSA) infections, in hospital settings. Replidyne is also pursuing the development of other novel anti-infective products based on its in-house discovery research.
Safe Harbor
This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company’s ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company’s product candidates and the Company’s ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company’s ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company’s sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company’s Form S-1 and most recent periodic report filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC’s electronic data gather analysis and retrieval system (EDGAR) at www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.
Replidyne, Inc.
CONTACT: Investor Relations of Replidyne, Inc., +1-303-996-5522
Web site: http://www.replidyne.com/
